Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
批准号:
10227725
负责人:
Massimo Loda
金额:
$212.28万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-30 至 2023-07-31
关键词:
AddressBiological MarkersBiologyBiostatistics CoreCancer BiologyCaringCenter for Translational Science ActivitiesCessation of lifeChronicClinicClinicalClinical MedicineClinical SciencesClinical TrialsCollaborationsCommunitiesDNA RepairDataDefectDetectionDevelopmentDiagnosisDiseaseDisease ManagementDisease ProgressionDrug resistanceEZH2 geneEarly Detection Research NetworkEarly DiagnosisEnsureEpigenetic ProcessFacultyFoundationsFutureGenomicsGoalsHeterogeneityIndolentIndustrializationInfrastructureInstitutesInternationalKnowledgeLinkMYCN geneMalignant NeoplasmsMalignant neoplasm of prostateMedicineMentorsMetastatic Prostate CancerMissionMolecularMutationNeuroendocrine Prostate CancerPARP inhibitionPathologyPatient CarePatient-Focused OutcomesPatientsPrecision Medicine InitiativeProbabilityPrognosisQuality of lifeReproduction sporesResearchResearch PersonnelResourcesRisk AssessmentScientistThe Cancer Genome AtlasTrainingTranslational ResearchTranslationsUnited StatesWestern Worldadvanced prostate cancerandrogen deprivation therapyanticancer researchbasebiomarker-drivencancer carecancer genomicscancer research center directorcareercareer developmentcastration resistant prostate cancerclinical biomarkersclinical careclinical riskcohortexomeexperienceimprovedimproved outcomeinhibitor/antagonistliquid biopsymenmindfulnessmultidisciplinarynext generationnovelnovel markernovel strategiesnovel therapeutic interventionoptimal treatmentsoverexpressionovertreatmentprecision medicinepreclinical studyprogramsprostate cancer riskradiation responserepairedstandard of caresuccesstranslational cancer researchtranslational genomicstreatment choicetreatment strategy
中文摘要
总体汇总
前列腺癌(PCA)是西半球最常见的癌症之一,具有极端的临床表现。
和分子异质性。2015年,超过221,800名男性被诊断患有PCA,27,540人死于PCA。
美国的我们的威尔康奈尔医学(WCM)孢子在PCA将采取一种新颖的精准医学
病人护理的方法,这将使我们的转化研究目标与整个PCA的男性护理保持一致
江西篇章尽早检测侵袭性PCA将避免效果较差的晚期治疗。我们
将研究如何改善局部PCA男性的风险评估,以实现最佳治疗选择,
主动监视(Active Surveillance,AS)晚期PCA男性,尽管接受了下一代雄激素治疗
剥夺疗法(ADT),屈服于耐药性和疾病进展。我们需要优化护理
通过新的生物标志物和治疗策略,将致命的PCA转变为一种可控制的慢性疾病。
我们注意到其他领域的知识可以增强我们的研究。我们会积极利用
发展研究计划将来自丰富的多机构环境的研究人员带到
专注于PCA翻译研究。一个可持续的SPORE计划需要发展的职业生涯,
初级教师(职业提升计划),谁将在该领域的领导者在未来几年。水平
垂直科学合作将确保我们利用其他领域的专业知识和经验,
SPOREs、早期检测研究网络(EDRN)、Stand Up 2 Cancer(SU2C)和前列腺
癌症基金会(PCF)计划。最后,我们将确保我们的研究所产生的资源和数据
将提供给研究界。我们的首要目标是从最初的PCA护理
通过使用精确医学方法管理晚期疾病进行诊断,
目前的临床护理。
总之,PCA中的WCM SPORE将成为范式转换翻译研究的主要中心。我们将
建立治疗PCA的新方法,这将导致改善患者生存和生活质量。
英文摘要
OVERALL SUMMARY
Prostate cancer (PCA) is one of the most common cancers in the Western hemisphere, with extreme clinical
and molecular heterogeneity. In 2015, over 221,800 men were diagnosed with—and 27,540 died from—PCA in
the United States. Our Weill Cornell Medicine (WCM) SPORE in PCA will take a novel precision medicine
approach to patient care, which will align our translational research goals with the care of men across the PCA
spectrum. The earliest possible detection of aggressive PCA will avoid less effective late-stage therapies. We
will study how to improve risk assessment in men with localized PCA to enable optimal treatment choices,
including active surveillance (AS). Men with advanced PCA, despite treatment with next generation androgen
deprivation therapy (ADT), succumb to drug resistance and disease progression. We need to optimize care
through novel biomarker and treatment strategies to change lethal PCA to a chronic manageable disease.
We are mindful that knowledge from other fields can augment our research. We will actively use the
Developmental Research Program to bring investigators from across a rich, multi-institutional landscape to
focus on PCA translational research. A sustainable SPORE program requires development of the careers of
junior faculty (Career Enhancement Program), who will be the leaders in the field for years to come. Horizontal
and vertical scientific collaborations will ensure that we leverage expertise and experience across other
SPOREs, the Early Detection Research Network (EDRN), and the Stand Up 2 Cancer (SU2C) and Prostate
Cancer Foundation (PCF) programs. Lastly, we will ensure that resources and data generated from our studies
will be made available to the research community. Our overarching goal is to impact PCA care from initial
diagnosis through management of advanced state disease using precision medicine approaches to improve
current clinical care.
In summary, the WCM SPORE in PCA will be a major hub for paradigm-shifting translational research. We will
establish new approaches to treating PCA, which will result in improved patient survival and quality of life.
期刊论文(54)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.
前列腺癌脑转移的DNA甲基化景观是由早期驱动器遗传改变塑造的。
DOI:
10.1158/0008-5472.can-22-2236
发表时间:
2023-04-14
期刊:
Cancer research
影响因子:
11.2
作者:
[]
通讯作者:
DOI:
10.1186/s13059-023-02865-5
发表时间:
2023-02-09
期刊:
Genome biology
影响因子:
12.3
作者:
[]
通讯作者:
DOI:
10.1158/1541-7786.mcr-23-0045
发表时间:
2023-06-01
期刊:
MOLECULAR CANCER RESEARCH
影响因子:
5.2
作者:
[Venkadakrishnan, Varadha Balaji, Yamada, Yasutaka, Weng, Kenny, Idahor, Osasenaga, Beltran, Himisha]
通讯作者:
Beltran, Himisha
DOI:
10.1038/s42003-021-02761-3
发表时间:
2021-11-02
期刊:
Communications biology
影响因子:
5.9
作者:
[Benelli M, Franceschini GM, Magi A, Romagnoli D, Biagioni C, Migliaccio I, Malorni L, Demichelis F]
通讯作者:
Demichelis F
DOI:
10.1038/s41416-022-02085-x
发表时间:
2023-04
期刊:
British journal of cancer
影响因子:
8.8
作者:
[Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PV, Loda M]
通讯作者:
Loda M
共 27 条
Core A: Pathobiology Core
-
批准号:10333947
-
项目类别:
-
资助金额:$55.38万
-
财政年份:2022
-
负责人:Massimo Loda
-
依托单位:
Core A: Pathobiology Core
-
批准号:10612365
-
项目类别:
-
资助金额:$40.87万
-
财政年份:2022
-
负责人:Massimo Loda
-
依托单位:
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
-
批准号:9763515
-
项目类别:
-
资助金额:$212.28万
-
财政年份:2017
-
负责人:Massimo Loda
-
依托单位:
Targeting the p110beta isoform of PI3 kinase in prostate cancer
-
批准号:9248261
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2015
-
负责人:Massimo Loda
-
依托单位:
Targeting the p110beta isoform of PI3 kinase in prostate cancer
-
批准号:9036357
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2015
-
负责人:Massimo Loda
-
依托单位:
Targeting the p110beta isoform of PI3 kinase in prostate cancer
-
批准号:8886182
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2015
-
负责人:Massimo Loda
-
依托单位:
PALMITOYLATION SIGNATURE IN PROSTATE CANCER CELL LINES
-
批准号:8171371
-
项目类别:
-
资助金额:$0.71万
-
财政年份:2010
-
负责人:Massimo Loda
-
依托单位:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
-
批准号:7915834
-
项目类别:
-
资助金额:$33.07万
-
财政年份:2009
-
负责人:Massimo Loda
-
依托单位:
Molecular Link Between Metabolic Syndrome and Prostate Cancer
-
批准号:8761515
-
项目类别:
-
资助金额:$37.72万
-
财政年份:2008
-
负责人:Massimo Loda
-
依托单位:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
-
批准号:8111906
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2008
-
负责人:Massimo Loda
-
依托单位:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
-
批准号:7529009
-
项目类别:
-
资助金额:$35.03万
-
财政年份:2008
-
负责人:Massimo Loda
-
依托单位:
Molecular Link Between Metabolic Syndrome and Prostate Cancer
-
批准号:9312766
-
项目类别:
-
资助金额:$38.3万
-
财政年份:2008
-
负责人:Massimo Loda
-
依托单位:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
-
批准号:7694289
-
项目类别:
-
资助金额:$35.03万
-
财政年份:2008
-
负责人:Massimo Loda
-
依托单位:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
-
批准号:8301013
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2008
-
负责人:Massimo Loda
-
依托单位:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
-
批准号:7894829
-
项目类别:
-
资助金额:$35.03万
-
财政年份:2008
-
负责人:Massimo Loda
-
依托单位:
Tissue and Pathology Resources
-
批准号:7248222
-
项目类别:
-
资助金额:$18.87万
-
财政年份:2007
-
负责人:Massimo Loda
-
依托单位:
Tissue and Pathology Core
-
批准号:8933388
-
项目类别:
-
资助金额:$25.47万
-
财政年份:2007
-
负责人:Massimo Loda
-
依托单位:
Tissue and Pathology Core
-
批准号:8485726
-
项目类别:
-
资助金额:$30.27万
-
财政年份:2007
-
负责人:Massimo Loda
-
依托单位:
Tissue and Pathology Core
-
批准号:8933245
-
项目类别:
-
资助金额:$24.7万
-
财政年份:2007
-
负责人:Massimo Loda
-
依托单位:
Core 3
-
批准号:7314844
-
项目类别:
-
资助金额:$26.3万
-
财政年份:2007
-
负责人:Massimo Loda
-
依托单位:
海外基金